The FDA approved Kerendia in July 2021 for adults with chronic kidney disease associated with Type 2 diabetes to reduce the ...

Bayer AG BAYRY recently announced that the FDA had accepted its supplemental new drug application (sNDA) seeking approval for ...

Bayer's mineralocorticoid receptor antagonist (MRA) Kerendia hit the mark as a treatment for a common form of heart failure in the FINEARTS-HF study, setting up regulatory approvals, but there is ...

Bayer has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its kidney-disease drug Kerendia in certain people with heart failure.

Regulators are expected to make a decision in the third quarter of 2025 on Kerendia to treat patients with heart failure with ...

Bayer has claimed EU approval for Kerendia, its new drug for chronic kidney disease (CKD) in people with type 2 diabetes, as the company tries to build a role of the drug alongside rival therapies ...

Kerendia sales surged 62%, mainly due to a substantial rise in volumes in the United States and business expansion in China. However, sales of oral anticoagulant Xarelto, co-developed with J&J JNJ ...